16
Participants
Start Date
March 1, 2018
Primary Completion Date
February 28, 2023
Study Completion Date
February 28, 2023
Fluoxetine
Patients enrolled into Phase II will be prescribed 2 weeks of short-acting fluoxetine 20 mg and will be instructed to take the prescription daily for 2 weeks. Then patients will be prescribed 10 additional weeks of 90 mg (weekly) fluoxetine and will be observed taking it once weekly at the dialysis unit. At the end of the 12 week study period, participants will be provided 4 additional weeks of 90 mg fluoxetine in order to provide sufficient time to follow up with their primary care physician or nephrologist.
MetroHealth Medical Center, Cleveland
MetroHealth Medical Center
OTHER